Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3OTHER_GOV 1OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 4Genitourinary 4Gastrointestinal 3Other solid neoplasm 2Tumor-Agnostic 1Head & Neck 1

Conditions

Carcinoma, Hepatocellular 2Esophageal Squamous Cell Carcinoma 1Carcinoma 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × sitravatinib × Gastrointestinal × Clear all
NCT05461794 2025-06-13

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

BeiGene

Phase 2 Terminated
96 enrolled 17 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03941873 2024-10-26

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

BeiGene

Phase 1/2 Completed
111 enrolled 22 charts
Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

NCT05564338 2023-06-07

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

BeiGene

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡